T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020 by Annie De Groot | Jun 30, 20202020 TCWP
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide by Annie De Groot | Sep 9, 2019EpiVax_PANDA_Taspoglutide_April_19_Final
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics by Sarah Moniz | Aug 15, 2018
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation by Sarah Moniz | Aug 15, 2018
Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies. by Sarah Moniz | Apr 10, 2018